SYNTHETIC CONJUGATED ESTROGENS A
Clinical safety rating: avoid
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
Synthetic conjugated estrogens bind to estrogen receptors (ERα and ERβ) in target tissues, activating genomic and non-genomic signaling pathways that regulate gene transcription and cellular functions.
| Metabolism | Primarily hepatically metabolized by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9) and conjugation with glucuronide and sulfate. Enterohepatic recirculation occurs. |
| Excretion | Renal excretion of conjugated metabolites accounts for approximately 50-80% of elimination. Fecal/biliary excretion is minor (<10%). |
| Half-life | Terminal elimination half-life is 13-27 hours for estrone conjugates, allowing once-daily dosing. |
| Protein binding | Approximately 95% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Apparent Vd is 2-4 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Oral bioavailability is 30-50% due to first-pass metabolism. |
| Onset of Action | Oral: 2-4 weeks for therapeutic effects on vasomotor symptoms; effects on vaginal epithelium may appear within 2 weeks. |
| Duration of Action | Duration is approximately 24 hours with daily dosing; effects on bone mineral density require continuous therapy of months to years. |
0.3 mg orally once daily
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment, reduce dose by 50%. |
| Pediatric use | Not indicated for use in pediatric patients |
| Geriatric use | Use lowest effective dose; monitor for thromboembolic events and malignancy risk |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| FDA category | Positive |
| Breastfeeding | Excreted in human breast milk; M/P ratio not established. Based on limited data, estrogens may reduce milk production and quality. Use during breastfeeding is contraindicated due to potential adverse effects on the infant, including estrogenic effects. |
| Teratogenic Risk |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer. Unopposed estrogen therapy in women with a uterus is associated with increased risk of endometrial hyperplasia and carcinoma. Estrogen-alone therapy may increase risk of invasive breast cancer. Estrogen plus progestin therapy increases risk of breast cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction.
| Common Effects | osteoporosis prevention |
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known or suspected breast cancer","Known or suspected estrogen-dependent neoplasia","Active or history of venous thromboembolism or arterial thromboembolism","Known thrombophilic disorders (e.g., protein C, protein S, or antithrombin deficiency)","Known or suspected pregnancy","Severe hepatic impairment or disease","Hypersensitivity to estrogens or any ingredient in the formulation"]
| Precautions | ["Cardiovascular disorders: increased risk of stroke, DVT, and MI","Malignant neoplasms: increased risk of endometrial and breast cancer","Gallbladder disease: increased risk","Hypercalcemia: may occur in women with breast cancer and bone metastases","Visual abnormalities: discontinue if sudden partial or complete loss of vision occurs","Hepatic impairment: use with caution in patients with impaired liver function","Fluid retention: monitor patients with conditions that may be exacerbated by fluid retention","Hypothyroidism: estrogen therapy increases thyroid-binding globulin levels","Lipid disorders: may increase triglycerides","Hereditary angioedema: may exacerbate symptoms"] |
Loading safety data…
| Category X: contraindicated in pregnancy. First trimester: high risk of fetal urogenital abnormalities, cardiac defects, and limb reduction. Second and third trimesters: associated with vaginal adenosis, clear cell adenocarcinoma in female offspring, and neurodevelopmental delays. Use during pregnancy may cause fetal harm, including spontaneous abortion and congenital malformations. |
| Fetal Monitoring | Not applicable as use is contraindicated in pregnancy. If inadvertent exposure, monitor for fetal growth restriction, congenital anomalies via ultrasound, and maternal blood pressure. Assess fetal heart rate patterns. Long-term follow-up for potential carcinogenesis in offspring recommended. |
| Fertility Effects | Estrogens can interfere with ovulation by inhibiting gonadotropin secretion. May reduce fertility during use; fertility returns upon discontinuation. No long-term effects on fertility reported. Contraceptive-like effects at high doses. |